Nourish raises $70M Series B led by JPMorgan to expand insurance-covered dietitian network

Summary

Nourish, a telehealth platform connecting chronic condition patients with registered dietitians covered by insurance, has raised a $70 million Series B led by JPMorgan's growth equity fund. Existing investors Index Ventures, Thrive, and Box Group all participated.

Co-founder and CEO Aiden Dure describes a business built on regulatory groundwork laid well before Nourish existed. Medicare began covering dietitian care in 2005 after seeing measurable ROI. The Affordable Care Act carved it out as a preventative benefit in 2009, and commercial payers followed. The more recent unlock was COVID-era telehealth parity — insurance covering virtual visits at the same rate as in-person — which made the model scalable. Nourish is roughly three years old.

The platform now has over 3,000 dietitians and has served hundreds of thousands of patients, the vast majority of whom pay nothing out of pocket. Nourish is in-network with most major commercial payers, Medicare, and some Medicaid plans.

Insurance infrastructure as the moat

The core operational challenge most dietitians historically avoided — negotiating directly with large insurers, then managing credentialing, licensing, and billing — is what Nourish has built as its competitive advantage. Most of that infrastructure is proprietary. The one external dependency is Candid Health, an API-forward billing platform Nourish uses for claims processing.

JPMorgan lead investor Paris Haymon previously worked at Index Ventures, where he was part of the team that ran Nourish's Series A, which made the process more continuity than cold pitch.

GLP-1s as tailwind, not threat

The GLP-1 explosion has been a net positive for Nourish, though Dure is careful to frame the drugs as a complement rather than a substitute. Nourish dietitians had been working with GLP-1 patients on diabetes management long before the weight-loss wave hit. Now, the platform has built a structured care model across the full GLP-1 journey: a step-therapy program before patients start medication, a companion program to manage side effects and maximize efficacy while on it, and a third track focused on sustainable weight maintenance after stopping.

The outcome data Dure cites is pointed: patients pairing a dietitian with a GLP-1 lose roughly 33% more weight than those taking the drug alone. For insurers who have spent heavily on GLP-1 coverage, rebound weight gain after patients stop the medication is a real ROI problem — one Nourish pitches itself as solving.

AI as augmentation, not replacement

Dure frames the human-AI split as roughly 80/20. About 80% of nutrition outcomes come from behavior change and accountability, where a human dietitian is hard to replicate. The remaining 20% — educational content, diet information, personalization — is where LLMs are genuinely useful and where Google historically underdelivered. Nourish is building AI tools into the app for both the dietitian and the patient, positioning the combination of human accountability and AI-assisted education as the superior care model. The dataset from hundreds of thousands of patient interactions is the claimed edge for training and refining those tools.

The $70 million will go toward scale and outcomes — expanding the dietitian network and deepening care quality — though Dure did not break down the specific allocation.